2. Others
  3. Isotope-Labeled Compounds
  4. 1415692-17-9

1415692-17-9

(Rac)-Bepotastine besilate Chemical Structure

1415692-17-9

Chemical Structure

  • (Rac)-Bepotastine besilate
  • CAS No: 1415692-17-9
    Formula: C27H31ClN2O6S
    Molecular Weight: 547.06
  • IUPAC Name: 4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1)
  • InChIKey: UDGHXQPQKQPSBB-UHFFFAOYSA-N
  • SMILES: O=S(C1=CC=CC=C1)(O)=O.O=C(CCCN2CCC(CC2)OC(C3=NC=CC=C3)C4=CC=C(C=C4)Cl)O

Biological Activity: (Rac)-Bepotastine (besilate) is the isomer of Bepotastine (besilate) (HY-A0015), and can be used as an experimental control. Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research[1][2][3][4].

Cat. No. Product Name Purity Description
HY-A0015A (Rac)-Bepotastine besilate 99.52% (Rac)-Bepotastine (besilate) is the isomer of Bepotastine (besilate) (HY-A0015), and can be used as an experimental control. Bepotastine besilate is a selective and orally active second-generation histamine H1 receptor antagonist, can suppress the expression of nerve growth factor (NGF). Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.

References

[1]. Kida T, et al. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010 Jul;91(1):85-91. [Content Brief]
[2]. Kamata Y, et al. Bepotastine besilate downregulates the expression of nerve elongation factors in normal human epidermal keratinocytes. J Dermatol Sci. 2018 Apr 23:S0923-1811(18)30186-5. [Content Brief]
[3]. Tanizaki H, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol. 2008;145(4):277-82. [Content Brief]
[4]. Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38. [Content Brief]

Keywords:

(Rac)-Bepotastine besilate